Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ragweed

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    23 result(s) found for: Ragweed. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2006-005713-35 Sponsor Protocol Number: RPE 04 Start Date*: 2007-03-20
    Sponsor Name:Curalogic A/S
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL MICROENCAPSULATED RAGWEED POLLEN EXTRACT ADMINISTERED PRIOR TO AND DURING THE RAGWEED ...
    Medical condition: Treatment of seasonal allergic rhinitis to ragweed pollen.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004341-27 Sponsor Protocol Number: MK-3641-008 Start Date*: 2016-01-05
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed (Ambrosia artemisiifolia) Sublingual Immunotherapy Tablet, in Children With a Histo...
    Medical condition: Rhinoconjunctivitis due to ragweed allergy
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) HR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-004522-10 Sponsor Protocol Number: Lais-Amb-11 Start Date*: 2012-05-06
    Sponsor Name:LOFARMA
    Full Title: Study on the efficacy and safety of three different doses of Lais Ambrosia tablets in patients with allergic rhinoconjunctivitis to pollen of Ambrosia
    Medical condition: rhinoconjunctivitis allergic to ragweed pollen
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10054928 Allergy to plants PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-003864-20 Sponsor Protocol Number: P05234 Start Date*: 2009-04-14
    Sponsor Name:Schering Plough Research Institute, a Division of Schering Corporation
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Long-Term Safety of Ragweed (Ambrosia artemisiifolia) Sublingual Tablet (SCH 39641) in ...
    Medical condition: Rhinoconjunctivitis due to ragweed allergy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-004431-38 Sponsor Protocol Number: Lais-Ragweed-15-16 Start Date*: 2015-03-05
    Sponsor Name:Lofarma S.p.A.
    Full Title: Double-blind, placebo-controlled, parallel-group, randomized multicentre study to assess the efficacy and safety of LAIS® Ragweed Sublingual tablet in patients with allergic rhinoconjunctivitis to ...
    Medical condition: Patients with allergic rhinoconjunctivities to ragweed pollen with or without asthma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004538-18 Sponsor Protocol Number: RPE 07 Start Date*: 2007-12-19
    Sponsor Name:Curalogic A/S
    Full Title: A randomized doble-blind placebo-controlled study to assess the safety in a one-year of orally administered microencapsulated ragweed pollen extract
    Medical condition: Patients with ragweed pollen allergy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-001682-41 Sponsor Protocol Number: HLS03/2011 Start Date*: 2011-05-09
    Sponsor Name:AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)
    Full Title: Comparison of the efficacy and the safety of different schedules of administration of sub-lingual immunotherapy in patients with ragweed pollinosis: a phase III randomized and controlled clinical s...
    Medical condition: Subjects who are allergic to Ragweed.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002096-42 Sponsor Protocol Number: 6057-PR-PRI-188 Start Date*: 2012-09-18
    Sponsor Name:LETI Pharma GmbH
    Full Title: Biological Standardization of Ambrosia elatior Allergen Extract Determination of the Biological Activity in HEP units. An Open Monocenter Study.
    Medical condition: Allergy to Ambrosia elatior (ragweed)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10036664 Prick test LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020079-22 Sponsor Protocol Number: DG40.08 Start Date*: Information not available in EudraCT
    Sponsor Name:STALLERGENES S.A.
    Full Title: Determination of sensitivity and specificity of five solutions of allergen extract (5 grasses, birch, ragweed pollens and Dermatophagoides pteronyssinus and Dermatophagoides farinae mites) for diag...
    Medical condition: Allergy to grass pollen Allergy to birch pollen Allergy to ragweed pollen Allergy to mites
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039085 Rhinitis allergic LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004616-19 Sponsor Protocol Number: ABT-gpCPT001 Start Date*: 2018-09-12
    Sponsor Name:ASIT biotech S.A.
    Full Title: A dose-ranging clinical study to determine the range of grass pollen allergen (gpCPT+) concentrations to be used in a conjunctival provocation test to grade moderate to severe grass pollen allergic...
    Medical condition: This clinical trial aims to evaluate a conjunctival provocation test (CPT) with the IMP gpCPT+ for the assessment and grading of grass pollen allergic rhinoconjunctivitis. Thus, a diagnostic solu...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001822-89 Sponsor Protocol Number: SMART_1_2012 Start Date*: 2012-08-21
    Sponsor Name:Lofarma S.p.A.
    Full Title: A Dose Finding Study of the Efficacy of LAIS® Birch-Alder tablets in patients suffering from tree pollen-induced allergic rhinoconjunctivitis
    Medical condition: Patients suffering from allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004473-26 Sponsor Protocol Number: LT0427-PII-01/07 Start Date*: 2007-10-16
    Sponsor Name:Laboratoires Théa
    Full Title: Efficacy and safety of sodium cromolyn eye drops compared with placebo eye drops in patients with a history of allergic conjunctivitis using the Conjunctival Allergen Challenge model.
    Medical condition: allergic conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001709 Allergic conjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021170-11 Sponsor Protocol Number: MOP4843g Start Date*: 2011-01-19
    Sponsor Name:GENENTECH, Inc.
    Full Title: A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF INTRAVENOUS MEMP1972A IN THE PREVENTION OF ALLERGEN...
    Medical condition: asthma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003553 Asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001345-18 Sponsor Protocol Number: HZA109912 Start Date*: 2007-07-26
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A 19-week, randomized, double-blind, placebo-controlled, three-period, cross-over pilot study comparing the effect of salmeterol/fluticasone propionate 50/100mcg BID, fluticasone propionate 100mcg ...
    Medical condition: Asthma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-010937-38 Sponsor Protocol Number: CIGE025AFR05 Start Date*: 2015-01-28
    Sponsor Name:Novartis Pharma S.A.S.
    Full Title: A 16-week treatment, multicenter, randomized, double blind, placebo-controlled, parallel-group study to assess the effect of omalizumab on the expression of FcεRI receptors of blood basophils and d...
    Medical condition: severe persistent non-atopic asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-002248-95 Sponsor Protocol Number: BOFT-0418-SAFE Start Date*: 2018-09-26
    Sponsor Name:FAES FARMA S.A.
    Full Title: Multi-centre, randomised, double blind, placebo-controlled, parallel, phase III study to assess the safety, tolerability and efficacy of bilastine ophthalmic solution 0.6% in adults
    Medical condition: Allergic Conjunctivitis (AC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001709 Allergic conjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) HU (Completed) SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-002174-23 Sponsor Protocol Number: SMART_5 Start Date*: 2011-11-21
    Sponsor Name:Lofarma S.p.A.
    Full Title: A dose Finding Study of the Efficacy of LAIS Grass tablets in patients suffering from grass pollen-induced allergic rhinoconjunctivitis
    Medical condition: allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004464-24 Sponsor Protocol Number: P04608 Start Date*: 2006-04-21
    Sponsor Name:Integrated Therapeutics Group, Inc
    Full Title: A Double-blind, Placebo-controlled, Randomized, Parallel-group Multicenter Study of Mometasone Furoate Nasal Spray on Sleep Disturbances and Daytime Somnolence in Subjects with Symptomatic Seasonal...
    Medical condition: Seasonal Allergic Rhinitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) GB (Completed) NL (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000416-28 Sponsor Protocol Number: 6043-PG-PSC-192 Start Date*: 2012-08-22
    Sponsor Name:LETI Pharma GmbH
    Full Title: A Randomised, Double-Blind, Parallel Group, Multicentre Study to Assess the Efficacy and Safety of Four Concentrations of Depigoid® Phleum in Patients with Allergic Rhinitis and/or Rhinoconjunctivi...
    Medical condition: Allergic Rhinitis and/or Rhinoconjunctivitis with or without Intermittent Asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    14.1 100000004855 10001705 Allergic asthma LLT
    14.1 100000004855 10001723 Allergic rhinitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-005321-78 Sponsor Protocol Number: CQAW039X2201 Start Date*: 2013-04-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, parallel group study evaluating efficacy and safety of QAW039 in the treatment of patients with moderate to severe atopic dermatitis
    Medical condition: Atopic dermatitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) BE (Completed) NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 20 14:32:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA